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Introduction
Flavin-containing monooxygenases (FMOs) (EC-1.14.13.8) oxygenate numerous drugs and xenobiotics containing soft nucleophiles, predominantly nitrogen and sulfur (Cashman, 1995; Ziegler, 2003) . Eleven distinct FMO genes exist, encoding five active enzymes (FMO1-5), the remaining six representing functional pseudogenes (Hernandez et al., 2004; Hines et al., 2002; Lawton et al., 1994) . FMO2 is expressed at high levels in the lung of most mammals including non-human primates (Karoly and Rose, 2001; Krueger et al., 2001; Williams et al., 1985; Yueh et al., 1997) . In humans, a genetic polymorphism has been described (Dolphin et al., 1998; Furnes et al., 2003; Krueger et al., 2002b; Whestine et al., 2000) in which all Caucasians and Asians genotyped to date have two FMO2*2A alleles. The FMO2*2A allele has a C>T transition at codon 472 (g.23,238C>T) resulting in a conversion of a glutamine to a stop codon (p.Q472X), yielding inactive protein (Dolphin et al., 1998) . Twenty-six percent of AfricanAmericans possess at least one FMO2*1 allele (p.Q472) encoding a full-length, functional enzyme (FMO2.1). Preliminary studies documented that the FMO2*1 allele was also present in individuals of Hispanic descent at a frequency of about 5% (Krueger et al., 2002b) . In this study, we present genotyping data from 632 Hispanic individuals and conclude that a significant difference exists in FMO2*1 allelic frequency between individuals of Puerto Rican and Mexican descent. We have recently demonstrated that FMO2.1 functions in the bioactivation of thioureas such as ethylenethiourea and α-naphthylthiourea (Henderson et al., 2004b) and in the potential detoxication of organophosphate insecticides such as phorate and disulfoton (Henderson et al., 2004a) . Thus, Hispanic and African-American individuals with the FMO2*1 allele may exhibit distinct outcomes compared to the general population following environmental or occupational exposures to such chemicals or in therapeutic response to drugs that are substrates for FMO2.1. This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods
Genomic DNA used for genotyping experiments was obtained, without identifiers, from seven sources (Table 1) . Hispanic samples were obtained as donor organs, or from living donors as blood or DNA. Ethnicity was self-reported by living donors. Criteria used included two generations of immediate ancestors from the same country (Zheng et al., 2003) , three generations of immediate ancestors from the same country (Genomics Collaborative, Inc.) and unascertained extended ancestry (balance of sample sources). The appropriate Institutional Review Boards approved studies prior to initiation of experiments. All donor samples were obtained with informed consent. DNA was isolated from donor samples as described elsewhere (Krueger et al., 2002b; Zheng et al., 2003) .
Sequence variations in human FMO2 were described according to the recommendations of den Dunnen and Antonarakis (2001) . Genbank accession AL021026 was used as the genomic reference sequence for FMO2 numbering (g.1 to g.23,432 begins with nucleotide A from M1 and ends with nucleotide G from X536). Reference to the cDNA or the inferred protein sequence is indicated with a lowercase c or p prefix, respectively. Allelic and protein designations used (eg. FMO2*1 and FMO2.1, respectively) are consistent with recommendations of the Human Nomenclature Committee (Shows et al., 1987) and were first applied to FMO2 variants by Whetstine et al., (2000) .
Allele discrimination methods were designed that would yield allele-specific polymerase chain reaction (PCR) products detectable by electrophoresis. Allele-specific oligonucleotides DMD #1099R -6 -described (Krueger et al., 2002b) , for 290 samples (Table 1 , first six sample sources). ASO primer hF2-42 (5'-CGGACCCTGCAACTCCTtTC-3') was substituted for hF2-15 for the remaining samples. The two alternative FMO2*1-specific forward primers are identical except for the incorporation of a single nucleotide mismatch (lower case t) designed into hF2-42 to enhance product specificity in late PCR cycles. PCR amplification conditions were identical to those already reported; however the cycle number was dropped from 40 to 30. The 230-bp FMO2*1 PCR product was separated from the 245-bp FMO2*2A (or 246-bp FMO2*2B) product by electrophoresis using 6% polyacrylamide gels (Invitrogen, Carlsbad, CA) and 1x Tris-borate-EDTA running buffer (89 mM Tris base, 89 mM boric acid, 2 mM EDTA).
A 198-bp region from AA471 to AA536 was sequenced (Krueger et al., 2002b) 
Results and Discussion
In total we obtained and analyzed genomic DNA from 632 Hispanic individuals (Table   1) . We were able to assemble large sample numbers (Table 2 and Since the data were consistent with equal proportions across sources, data within an ethnic group were pooled before comparing the two ethnic groups. Results of this comparison are shown in Table 3 . There was strong evidence (p=0.0066) of a difference in the proportion of individuals having FMO2*1 among Hispanics of either Mexican or Puerto Rican descent. Puerto Ricans had a higher occurrence of FMO2*1 than did Mexican individuals. Blyth-Still-Casella 95% confidence intervals did not overlap (Table 3) We also were interested in the occurrence of g. 23,412-23,413insT (c.1588-1589insT) . To date this SNP has only been demonstrated in combination with g.23,238C>T (p.Q472X) and is designated as FMO2*2b (Furnes et al., 2003; Krueger et al., 2002b; Whetstine et al., 2000) ; however, if it were to occur as part of the p.Q472 haplotype the resulting frameshift would have the potential of altering the last six amino acids and adding 23 amino acids to the FMO2 carboxy-terminus. We sequenced genomic DNA (p.AA471-AA536) from the 32 individuals with the FMO2*1 allele (33, FMO2*1 alleles; 31, FMO2*2 alleles) and an additional 27 individuals homozygous for FMO2*2 (54 alleles). The g.23,412-23,413insT SNP was present in DNA from seven of the 59 individuals (118 chromosomes) examined. Three of these individuals were heterozygous for FMO2*1/*2, so this DNA was cloned to determine the phase of the two SNPs. In each case it was determined that the frame shift occurred in combination with the p.X472 haplotype (FMO2*2b). Thus the frequency of the frame shift was 8.2% of the FMO2*2 allele (7 of 85 FMO2*2 alleles sequenced).
In addition to the frame shift variant, three SNPs encoding silent sequence changes to their respective third codon positions were identified from the unphased sequencing data. Two of the SNPs, c.1497C>G (g.23,321C>G) and c.1587T>C (g.23,411T>C) were rare, occurring in only one and two individuals, respectively. Neither of these alterations which respectively encode p.L499 and p.F529 has previously been documented. The third SNP, c.1476A>G (g.23,300A>G) which encodes p.K492 was recently documented in an African American population (Furnes et al., 2003) but frequency information was not provided. This SNP may be an additional example of a variant with a frequency of occurrence that is dependent on the race or ethnicity of the group (Table 4) Although we have demonstrated active FMO2.1 is present in the lung from an FMO2*1/*2 individual (Krueger et al., 2002a) , our hypothesis, as yet untested, is that individuals of African or Hispanic descent expressing the FMO2*1 allele will exhibit either increased or decreased sensitivity to toxicity upon exposure to environmental chemicals for which the lung is a major route of exposure and/or target organ. For example, exposure to ethylenethiourea or α-naphthylthiourea may result in enhanced pulmonary toxicity as the sulfenic acid metabolites formed from thioureas by FMO are themselves reactive and promote oxidative stress through glutathione oxidation (Decker and Doerge, 1991; Henderson et al., 2004b; Krieter et al., 1984; Scott et al., 1990; Smith and Crespi, 2002) . In contrast, exposure to phorate or disulfoton through inhalation may result in less toxicity for these individuals as FMO is the predominant pulmonary phase I enzyme and the sole FMO metabolite is the sulfoxide, a considerably less toxic metabolite compared to the oxon metabolites produced by cytochrome P450 (Henderson et al., 2004a; Hodgson et al., 1998; Levi and Hodgson, 1988; Usmani et al., 2004) . However, the extent of toxicity will dependent on the regulation of FMO2 and the relative contribution by lung CYPs, since CYPs can further metabolize the oxon metabolite to the more toxic sulfoxide oxon (Kinsler et al., 1988) . This article has not been copyedited and formatted. The final version may differ from this version. 
